LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
B. Besse(Université Paris-Saclay), SH Lee(Samsung Medical Center), Shun Lü(Shanghai Jiao Tong University), Daniil Stroyakovskiy(Moscow City Oncology Hospital №62), O. Yazıcı(Gazi University), Jerónimo Rodríguez Cid(Hospital Médica Sur), H. Hayashi(Kindai University), Danny Nguyen(City Of Hope National Medical Center), James Chih‐Hsin Yang(National Taiwan University), Maya Gottfried(Meir Medical Center), Ana Caroline Zimmer Gelatti(Hospital São Lucas da PUCRS), Scott Owen(McGill University Health Centre), S. Ou(University of California, Irvine), Marguerite Ennis(Janssen (United States)), Seema Sethi(Janssen (United States)), J.M. Bauml(Janssen (United States)), J. Zhang(Janssen (United States)), J.C. Curtin(Janssen (United States)), B.C. Cho(Yonsei University)
Cited by 42Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis